SCHEMBL2002799

SCHEMBL2002799

O=C(O)CCCC(Sc1ccccn1)N1C(=O)CCC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.38
HSD17B10 Q99714 3/20 0.38
HPGD P15428 2/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
RECQL P46063 1/20 0.38
PKM P14618 1/20 0.36
TBXAS1 P24557 1/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TBXA2R P21731 2/20 0.34
POLB P06746 1/20 0.34
DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL616909 0.85 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL7753044 0.80 POLB (0.39) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL177981 0.79 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL5162362 0.78 HPGD (0.38) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL6687766 0.76 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL177980 0.71 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL2002797 0.71 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL28380361 0.71 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2HSD17B10KMT2AMAPT
SCHEMBL616908 0.71 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A
SCHEMBL21768790 0.71 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HSD17B10HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150175701-A1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2015-06-25 US disclosed
US-8906369-B2 Ovr110 antibody compositions and methods of use DIADEXUS, INC. (US) 2014-12-09 US disclosed
US-20130232589-A1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2013-09-05 US disclosed
US-8444971-B2 OVR110 antibody compositions and methods of use DIADEXUS, INC. (US) 2013-05-21 US disclosed
US-8354508-B2 PRO115 antibody compositions and methods of use DIADEXUS, INC. (US) 2013-01-15 US disclosed
US-8207311-B2 Ovr115 antibody compositions and methods of use DIADEXUS, INC. (US) 2012-06-26 US disclosed
US-8148093-B2 Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk DIADEXUS, INC. 2012-04-03 US disclosed
EP-1633784-B1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS INC (US) 2011-07-13 EP disclosed
US-20110159516-A1 PCan065 Antibody Compositions and Methods of Use DIADEXUS, INC. (US) 2011-06-30 US disclosed
US-7964195-B2 Using immunoglobulin which preferentially binds cancer specific antigen (OVR110) as treatment for head and neck or endometrial cancer DIADEXUS, INC. 2011-06-21 US disclosed
US-20100150907-A1 PRO115 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2010-06-17 US disclosed
US-20100136009-A1 OVR110 Antibody Compositions and Methods of Use DIAZYME LABORATORIES, INC. 2010-06-03 US disclosed
US-20070104647-A1 Ovr115 antibody compositions and methods of use DIAZYME LABORATORIES, INC. 2007-05-10 US disclosed